Skip to main content

Mechanisms of Action

How Ibogaine & Noribogaine Work

Five clinician-grade deep-dives into the molecular targets, signaling cascades, and pharmacokinetics that explain why a single supervised flood-dose can produce sustained anti-craving and mood-stabilizing effects long after the parent drug clears.

DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team

Quick Answer

How does ibogaine work?

Ibogaine acts on multiple targets simultaneously: mu-opioid receptors (modulating withdrawal), NMDA receptors (non-competitive antagonism that attenuates opioid tolerance), BDNF and GDNF upregulation (driving long-tail neuroplasticity and dopaminergic repair), and serotonin/sigma-2/nicotinic receptors. Its long-half-life metabolite noribogaine (28-49h) is the species responsible for most of the post-flood clinical effect. Together these mechanisms make ibogaine a psychoplastogen: a compound that drives rapid, sustained synaptic remodeling rather than just symptomatic blockade.

Reviewed by Dr. Arellano, M.D. (May 2026)

BDNF & GDNF Upregulation

Ibogaine and noribogaine upregulate brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), driving downstream neuroplasticity and dopaminergic repair.

Mu-Opioid Receptor

Ibogaine and noribogaine interact with the mu-opioid receptor at low affinity, but the clinical effect on opioid withdrawal is multifactorial, not a simple substitute-and-taper.

NMDA Receptor Antagonism

Ibogaine is a non-competitive NMDA receptor antagonist: a mechanism it shares with ketamine, dextromethorphan, and memantine, with implications for tolerance reversal and dissociative experience.

Ibogaine Pharmacokinetics

Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination, including the long noribogaine tail that drives the post-flood telemetry window.

Noribogaine: The Long-Tail Metabolite

Noribogaine is ibogaine's CYP2D6-formed metabolite: cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.

Methodological Note

These are mechanism explainers, not personal medical advice.

The clinical evidence base for ibogaine is substantially smaller than for FDA-approved medications. Where receptor and signaling data are extrapolated from rodent or in-vitro work, we say so explicitly. For human-clinical context, see the 2026 evidence base review and the onsite taper cohort methodology page.

Clinical Calls

Have a clinical question about mechanism?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation

Continue Your Research

Where to go next

Popular next steps for visitors researching treatment. This section personalizes as you explore.